142 related articles for article (PubMed ID: 10554834)
1. De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome.
Yamaguchi M; Ohno T; Oka K; Taniguchi M; Ito M; Kita K; Shiku H
Br J Haematol; 1999 Jun; 105(4):1133-9. PubMed ID: 10554834
[TBL] [Abstract][Full Text] [Related]
2. Somatic hypermutations in the VH segment of immunoglobulin genes of CD5-positive diffuse large B-cell lymphomas.
Kume M; Suzuki R; Yatabe Y; Kagami Y; Miura I; Miura AB; Morishima Y; Nakamura S; Seto M
Jpn J Cancer Res; 1997 Nov; 88(11):1087-93. PubMed ID: 9439684
[TBL] [Abstract][Full Text] [Related]
3. De novo CD5+ diffuse large B-cell lymphomas express VH genes with somatic mutation.
Taniguchi M; Oka K; Hiasa A; Yamaguchi M; Ohno T; Kita K; Shiku H
Blood; 1998 Feb; 91(4):1145-51. PubMed ID: 9454743
[TBL] [Abstract][Full Text] [Related]
4. Cytogenetic analysis of de novo CD5-positive diffuse large B-cell lymphoma.
Kaneko H; Shimura K; Horiike S; Kuroda J; Matsumoto Y; Yokota S; Nishida K; Ohkawara Y; Taniwaki M
Asia Pac J Clin Oncol; 2011 Dec; 7(4):346-50. PubMed ID: 22151983
[TBL] [Abstract][Full Text] [Related]
5. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.
Matolcsy A; Chadburn A; Knowles DM
Am J Pathol; 1995 Jul; 147(1):207-16. PubMed ID: 7541611
[TBL] [Abstract][Full Text] [Related]
6. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.
Yamaguchi M; Seto M; Okamoto M; Ichinohasama R; Nakamura N; Yoshino T; Suzumiya J; Murase T; Miura I; Akasaka T; Tamaru J; Suzuki R; Kagami Y; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
Blood; 2002 Feb; 99(3):815-21. PubMed ID: 11806981
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma.
Tang H; Zhou H; Wei J; Liu H; Qian W; Chen X
Hematology; 2019 Dec; 24(1):446-454. PubMed ID: 31072235
[TBL] [Abstract][Full Text] [Related]
8. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes.
Harada S; Suzuki R; Uehira K; Yatabe Y; Kagami Y; Ogura M; Suzuki H; Oyama A; Kodera Y; Ueda R; Morishima Y; Nakamura S; Seto M
Leukemia; 1999 Sep; 13(9):1441-7. PubMed ID: 10482997
[TBL] [Abstract][Full Text] [Related]
9. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group.
Abou-Elella AA; Weisenburger DD; Vose JM; Kollath JP; Lynch JC; Bast MA; Bierman PJ; Greiner TC; Chan WC; Armitage JO
J Clin Oncol; 1999 Mar; 17(3):784-90. PubMed ID: 10071267
[TBL] [Abstract][Full Text] [Related]
10. De Novo CD5+ Primary Gastrointestinal Diffuse Large B-Cell Lymphoma: Challenges With Treatment and Clinical Course.
Ramachandran P; Sahni S; Wang JC
J Investig Med High Impact Case Rep; 2019; 7():2324709619893546. PubMed ID: 31814435
[TBL] [Abstract][Full Text] [Related]
11. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
Alinari L; Gru A; Quinion C; Huang Y; Lozanski A; Lozanski G; Poston J; Venkataraman G; Oak E; Kreisel F; Park SI; Matthews S; Abramson JS; Iris Lim H; Martin P; Cohen JB; Evens A; Al-Mansour Z; Singavi A; Fenske TS; Blum KA
Am J Hematol; 2016 Jun; 91(4):395-9. PubMed ID: 26800311
[TBL] [Abstract][Full Text] [Related]
12. [Multiple organ relapse in primary de novo CD5+ diffuse large B cell lymphoma of the bone after a complete response].
Nakayama S; Akioka T; Yokote T; Hara S; Oka S; Yamane K; Yamano T; Tsuji M; Hanafusa T
Rinsho Ketsueki; 2004 Feb; 45(2):149-54. PubMed ID: 15045824
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs.
Ueno S; Yamaguchi M; Kimura M; Odagiri H; Shiraki K; Uemoto S; Nakamura N; Zhang W; Shiku H; Kobayashi T
Int J Oncol; 2005 Nov; 27(5):1241-6. PubMed ID: 16211218
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma.
Park BB; Kim JS; Lee YY; Kang HJ; Ryoo BY; Kang JH; Kim HY; Kim BS; Oh SY; Kwon HC; Won JH; Kim K; Park K; Suh C; Kim WS
Leuk Lymphoma; 2008 Jan; 49(1):88-94. PubMed ID: 18203017
[TBL] [Abstract][Full Text] [Related]
15. De novo CD5+ diffuse large B-cell lymphomas. A heterogeneous group containing an unusual form of splenic lymphoma.
Kroft SH; Howard MS; Picker LJ; Ansari MQ; Aquino DB; McKenna RW
Am J Clin Pathol; 2000 Oct; 114(4):523-33. PubMed ID: 11026098
[TBL] [Abstract][Full Text] [Related]
16. De novo CD5 positive diffuse large B-cell lymphomas with bone marrow involvement in Korean.
Kong SY; Cho EH; Woo HY; Park Q; Ko YH; Kim SH
J Korean Med Sci; 2004 Dec; 19(6):815-9. PubMed ID: 15608391
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival.
Yoshioka T; Miura I; Kume M; Takahashi N; Okamoto M; Ichinohasama R; Yoshino T; Yamaguchi M; Hirokawa M; Sawada K; Nakamura S
Genes Chromosomes Cancer; 2005 Feb; 42(2):149-57. PubMed ID: 15543600
[TBL] [Abstract][Full Text] [Related]
18. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas.
Kobayashi T; Yamaguchi M; Kim S; Morikawa J; Ogawa S; Ueno S; Suh E; Dougherty E; Shmulevich I; Shiku H; Zhang W
Cancer Res; 2003 Jan; 63(1):60-6. PubMed ID: 12517778
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y
Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143
[TBL] [Abstract][Full Text] [Related]
20. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
